Sumatriptan Succinate
Brand names: Imitrex, Zembrace Symtouch, Onzetra Xsail, Sumatriptan Succinate
At a glance
- Medicare prescriptions, 2024
- 1,296,010
- Medicare drug cost
- $30.0M
- Average cost per prescription
- $23.12
- Clinicians who prescribed it
- 56,261
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
IMITREX tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with IMITREX, reconsider the diagnosis of migraine before IMITREX is administered to treat any subsequent attacks.
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 33.7%
- Internal Medicine 22.0%
- Nurse Practitioners 16.3%
- Neurology 15.7%
- Physician Assistants 6.9%
- General Practice 1.1%
- Pain Medicine 0.8%
- Geriatric Medicine 0.6%
- Physical Medicine & Rehabilitation (PM&R) 0.3%
- Sports Medicine 0.2%
- Hospitalist 0.2%
- Psychiatry 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 16% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +33%
- Rhode Island +31%
- Indiana +28%
- Kansas +26%
- Nevada +24%
- Mississippi (smallest change) +5%
- Kentucky (smallest change) +9%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
GlaxoSmithKline LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white triangle tablet, 9 mm | I 25 |
| 50 mg | white triangle tablet, 11 mm | IMITREX 50 |
| 100 mg | pink triangle tablet, 11 mm | IMITREX 100 |
Golden State Medical Supply, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 6 mm | M S4 |
| 50 mg | white round tablet, 8 mm | M S7 |
| 100 mg | white round tablet, 10 mm | M S12 |
Mylan Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 6 mm | M S4 |
| 50 mg | white round tablet, 8 mm | M S7 |
| 100 mg | white round tablet, 10 mm | M S12 |
Preferred Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white round tablet, 6 mm | C 32 |
Preferred Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | white capsule, 12 mm | C 34 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $48,921 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Tonix Medicines, Inc. $35,798
- Currax Pharmaceuticals LLC $13,124
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Apr 2022 · McKesson Medical-Surgical Inc. Corporate Office · Class II
cGMP deviations: Temperature abuse
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.